Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity ofBT7480 in Patients With Nectin-4 Associated Advanced Malignancies
Study of BT7480 in Patients with Advanced Cancer
Sponsor: BicycleTx Limited
Enrolling: Male and Female Patients
IRB Number: AAAU0713
U.S. Govt. ID: NCT05163041
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate whether the investigational drug, BT7480, will be a safe and effective anticancer therapy. This is the first time BT7480 will be given to humans. BT7480 is designed to recognize and attach itself to both the Nectin-4 protein found on the surface of some cancer cells and CD137, a protein found on the surface of some immune cells. BT7480 binds to both Nectin-4 and CD137 and may activate immune cells to fight the Nectin-4-expressing cancers. Cancers include bladder cancer, breast cancer, esophageal cancer, ovarian cancer, head and neck/oral cancers, lung cancer, and stomach cancer.
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with advanced cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162